Genitourinary Cancer
News from the FDA/CDC
FDA affirms bladder cancer warning with diabetes drug
The FDA reaffirmed its warning on the possible risk of bladder cancer associated with use of the type 2 diabetes drug pioglitazone.
Conference Coverage
Oncolytic virus active against bladder cancer
For patients with non-muscle invasive bladder cancer, intravesicular administration of an oncolytic virus was both feasible and safe, and in a...
Conference Coverage
Vaccine/PD-1 inhibitor combo shows early promise against mCRPC
National Harbor, MD. – To date, checkpoint inhibitors have shown little clinical activity as single agents against metastatic, castration-...
From the Journals
ADT not associated with increased risk of dementia in larger study
Treatment with androgen deprivation therapy (ADT) was not associated with an increased risk of dementia in a large, population-based study,...
New Therapies
Expanding treatment options and ongoing challenges for urologic cancers
Community Translations
Renal cell carcinoma approval adds another notch to cabozantinib’s belt
From the Journals
Cabozantinib bests sunitinib against metastatic RCC
Cabozantinib showed significant improvements in progression-free survival and objective response rate over standard-of-care sunitinib in a phase...
From the Journals
Targeting HER1/2 falls flat in bladder cancer trial
Treatment with lapatinib after chemotherapy does not improve survival in people with HER1- or HER2-positive metastatic urothelial bladder cancer...
From the Journals
Cancer survivors report two times greater medication use for anxiety and depression
Approximately 20% of adult cancer survivors in the United States – roughly 2.5 million – take medication for anxiety or depression, a rate that is...
From the Journals
ADT may increase dementia risk in prostate CA
Androgen deprivation thereapy, when used in the treatment of prostate cancer, seems to increase dementia risk.
Conference Coverage
Cabozantinib used as first-line therapy prolongs PFS for metastatic RCC
Cabozantinib offered longer progression-free survival than did sunitinib in first-line therapy for intermediate or poor-risk advanced RCC.